Principal Investigator
|
Title
|
Organization
|
Status
|
ID
|
Schwenkglenks, Matthias |
SwissPandemic&AmR-Health Economy Awareness Detect (Flagship project), Subproject 4: Societal and Health Economics |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Active |
4642275 |
Schwenkglenks, Matthias |
Gesundheitsökonomische Analyse von PsyYoung-Daten |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Active |
4643086 |
Schwenkglenks, Matthias |
Health economic analysis alongside DROPIT trial |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Active |
4659722 |
Schwenkglenks, Matthias |
Influenza vaccination policies and key factors related to their implementation in Europe |
Pharmazeutische Medizin ECPM |
Completed |
1201134 |
Schwenkglenks, Matthias |
Kostenmodell Etanercept-Biosimilar |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4354690 |
Schwenkglenks, Matthias |
Economic assessment of HBV treatments |
Pharmazeutische Medizin ECPM |
Completed |
1201224 |
Schwenkglenks, Matthias |
Cost-effectiveness of hyperkalemia treatment |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
3529269 |
Meier, Christoph R.; Schwenkglenks, Matthias |
Arzneimittelreport Schweiz |
Departement Public Health / Pharmazeutische Medizin (Szucs), Departement Pharmazeutische Wissenschaften / Klinische Pharmazie/Spitalpharmazie (Meier) |
Completed |
3706169 |
Meier, Christoph R.; Schwenkglenks, Matthias |
Arzneimittelreport Schweiz |
Departement Public Health / Pharmazeutische Medizin (Szucs), Departement Pharmazeutische Wissenschaften / Klinische Pharmazie/Spitalpharmazie (Meier) |
Completed |
2096475 |
Schwenkglenks, Matthias |
Economics of denosumab in metastatic bone disease |
Departement Public Health / Pharmazeutische Medizin ECPM |
Completed |
1201884 |
Schwenkglenks, Matthias |
Cost-effectiveness of novel multiple sclerosis drug |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4491692 |
Schwenkglenks, Matthias |
Cost-effectiveness of novel ophthalmology drugs |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4491703 |
Schwenkglenks, Matthias |
Health economics of bronchitol dry powder |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
1594329 |
Schwenkglenks, Matthias |
Cost-effectivness of chronic heart failure treatment |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
3008122 |
Schwenkglenks, Matthias |
Regulierungsfolgenabschätzung zur Einführung eines Referenzpreissystems in der Schweiz |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4485812 |
Schwenkglenks, Matthias |
Budget impact of GCSF biosimilars |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4529725 |
Schwenkglenks, Matthias |
Impact and economics of inclisiran in Switzerland |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4602761 |
Schwenkglenks, Matthias |
Impact of targeted therapy in patients with metastatic lung cancer |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4473765 |
Schwenkglenks, Matthias |
Cost-effectiveness analysis of acute heart failure treatment |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
2250318 |
Schwenkglenks, Matthias |
Cost-minimisation study of NSCLC treatments |
Pharmazeutische Medizin ECPM |
Completed |
1201131 |